The settlement ends the Sackler family’s ownership of the Oxycontin developer Pu...
The FDA has granted approval for the ANDA of Lupin’s Sacubitril and Valsartan Ta...
Adaptive logistics are vital for clinical trials, but there are challenges in na...
The FDA rejected the company’s initial NDA in 2021, citing the lack of an adequa...
Disc Medicine finalised the pivotal Phase III trial design of bitopertin in eryt...
The FDA reported that six patients died after being injected with Teva’s Copaxon...
Emcure Pharmaceuticals has opened its new formulation research and development (...
AbbVie and Neomorph are set to enter a partnership and option-to-license agreeme...
The Pharmaceutical Technology Excellence Awards winners have been announced! Dow...
The year ahead in clinical trials looks set to be one that is challenged and inf...
Biogen’s applications for the higher dose regimen of spinal muscular atrophy (SM...
A new report dives into the evolving clinical trial landscape and transformative...
The FDA has granted orphan drug designation (ODD) to Zai Lab’s ZL-1310, aimed at...
Emergent Biosolutions (Gaithersburg, US) has purchased US and Canadian rights to...
The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-o...
Junshi Biosciences and TopAlliance are set to enter a collaboration with LEO Pha...
